Trial Profile

Phase II trial of CEQ 508 for the prevention of colorectal cancer in patients with familial adenomatous polyposis.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CEQ 508 (Primary)
Indications Colorectal cancer; Familial adenomatous polyposis
Focus Therapeutic Use
Sponsors Cequent Pharmaceuticals

Most Recent Events

06 Jan 2012 Marina Biotech receives $US5 million in funds, which will in part aid in financing this trial, as reported in a company media release.
16 Apr 2010 Cequent expects to initiate this trial in 2011, according to a company media release.
16 Apr 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com